Skip to main content

Advertisement

Table 4 Ongoing studies of immune checkpoint inhibitors in ovarian cancer

From: The role of immune checkpoint inhibition in the treatment of ovarian cancer

Phase Trial number Trial Disease status Immunotherapy agent(s) Concurrent therapy
3 NCT02580058 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) recurrent platinum resistant Avelumab Liposomal Doxorubicin
3 NCT02718417 Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) primary Avelumab Carboplatin Paclitaxel
3 ENGOT-ov29-GCIG A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab recurrent platinum sensitive Atezolizumab Carboplatin-based chemotherapy Bevacizumab
2 NCT02440425 Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer recurrent platinum resistant Pembrolizumab Dose Dense Paclitaxel
2 NCT02498600 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer recurrent platinum sensitive/resistant Nivolumab +/- Ipilimumab  
2 NCT02520154 Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer primary Pembrolizumab Carboplatin Paclitaxel
2 NCT02659384 Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer recurrent platinum resistant Atezolizumab Bevacizumab Acetylsalicylic Acid
2 NCT02674061 Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) recurrent platinum sensitive/resistant Pembrolizumab  
2 NCT02764333 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer recurrent platinum resistant Durvalumab TPIV200/huFR-1 (anti-folate receptor vaccine)
2 NCT02766582 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer suboptimally cytoreduced primary Pembrolizumab Carboplatin Paclitaxel
1/2 NCT02431559 A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated recurrent platinum resistant Durvalumab Motolimod Pegylated Liposomal Doxorubicin
1/2 NCT02484404 Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer recurrent platinum sensitive/resistant Durvalumab Olaparib or Cediranib
1/2 NCT02485990 Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) recurrent or persistent Tremelimumab Olaparib
1/2 NCT02571725 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer BRCA-deficient recurrent platinum sensitive/resistant Tremelimumab Olaparib
1/2 NCT02657889 Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162) recurrent platinum resistant Pembrolizumab Niraparib
1/2 NCT02726997 Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer primary Durvalumab Carboplatin Paclitaxel
1 NCT02737787 A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer ≥2nd remission Nivolumab WT1 vaccine
0 NCT02728830 A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers primary Pembrolizumab